Benitec Biopharma Reports FY2026 Financial Results, Operational Update

What Happened

• On September 14, 2026, Benitec Biopharma Inc. (BNTC) issued a press release announcing its financial results for the fiscal year ended June 30, 2026 and providing an operational update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8‑K (Accession No. 0001193125-26-390539). The report was signed by Dr. Jerel A. Banks, Chief Executive Officer.
• The Form 8‑K is filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits). The Company furnished the press release as an exhibit to the filing.

Key Details

• Filing date: September 14, 2026 (Form 8‑K filed and press release dated the same day).
• Reporting period: fiscal year ended June 30, 2026.
• Exhibit: Press Release of Benitec Biopharma Inc., furnished as Exhibit 99.1.
• Authorized signature: Dr. Jerel A. Banks, Chief Executive Officer.

Why It Matters

• This 8‑K notifies investors that Benitec has released its FY2026 earnings and operational update; those results (revenue, net income/loss, cash position, program updates) will be in the press release exhibit and are material for assessing the company’s recent performance.
• Retail investors should review the Exhibit 99.1 press release for the specific financial figures and operational details, and monitor any follow-up SEC filings (e.g., 10‑K) for audited financial statements and additional context.